| C. novyi-NT spores | Clostridium Novyi-NT spores |
| CA-125 | Cancer antigen 125 |
| CA4P | Fosbretabulin tromethamine |
| CA4PD | Fosbretabulin disodium |
| CAB | Community Advisory Board |
| CABG | Aortocoronary bypass; Coronary artery bypass grafting |
| cAC10-vcMMAE | Brentuximab vedotin |
| CaCO3 | Calcium carbonate |
| CAD | Coronary artery disease; Coronary heart disease |
| Ca-DTPA | Pentetic acid calcium |
| CAF | CAF regimen; Caffeine |
| CAFdA | Clofarabine |
| CAI | Carboxyamidotriazole |
| CALGLUC | Calcium gluconate |
| CAM | Complementary and alternative medicine |
| CAMB | Encochleated amphotericin B |
| CAP-1 | Carcinoembryonic antigen peptide-1; CEA peptide-1 |
| CAPE | Capecitabine |
| CAPIRI | CAPIRI regimen; XELIRI regimen |
| CAPOX | CAPOX regimen |
| CAR | Chimeric antigen receptor |
| cART | Combination antiretroviral therapy; Highly active antiretroviral therapy |
| CART-19 cells | CD19CAR-CD3zeta-4-1BB-expressing allogeneic T lymphocytes |
| CART-BCMA | Autologous anti-BCMA-CAR-TCRz/4-1BB-expressing T lymphocytes CART-BCMA |
| CASAD | Calcium aluminosilicate anti-diarrheal |
| CB | Cinobufotalin |
| CBC | Blood cell count; Complete blood count; Full blood count |
| CBD | Cannabidiol |
| CBDCA | Carboplatin |
| CBDCA/IFF/VP-16 | ICE regimen |
| CBE | Clinical breast exam |
| CBN | Cannabinol |
| CBT | Cognitive behavior therapy; Cognitive therapy |
| CBT-1 | MDR modulator CBT-1 |
| CC-4047 | Pomalidomide; Pomalyst |
| CC-5013 | Lenalidomide; Revlimid |
| CCDI | Childhood Cancer Data Initiative |
| CCI-779 | Temsirolimus; Torisel |
| cCLB8 | anti-IL-6 chimeric monoclonal antibody; CNTO 328; Siltuximab; Sylvant |
| CCNB1 peptide-pulsed autologous dendritic cell vaccine | Cyclin B1 peptide-pulsed autologous dendritic cell vaccine |
| CCNU | Gleostine; Lomustine |
| ccRCC | Clear cell renal cell cancer; Clear cell renal cell carcinoma; Conventional renal cell carcinoma |
| CCSG | P30 Cancer Center Support Grant |
| CCTROP | Adrenocorticotropic hormone |
| CD117 | c-kit; Stem cell factor receptor |
| CD20 | CD20 antigen |
| CD22 CAR-T | anti-CD22 CAR-expressing T lymphocytes |
| CD24Fc | CD24 extracellular domain-IgG1 Fc domain recombinant fusion protein CD24Fc |
| CD3-HER2neu MOAB | Ertumaxomab |
| CD40L | Recombinant CD40-ligand |
| CD80 | B7-1 |
| CDBC | Dimethicone/polymer barrier cream |
| CDC | Centers for Disease Control and Prevention |
| CDDP | Cisplatin |
| CDHP | Gimeracil |
| CDP-choline | Citicoline |
| CDV | Cidofovir |
| CEA | Carcinoembryonic antigen |
| CEA PEP 1-6D | Carcinoembryonic antigen peptide 1-6D |
| CEA(6D) VRP vaccine | Carcinoembryonic antigen peptide 1-6D virus-like replicon particles vaccine |
| CEARNAVAC | Carcinoembryonic antigen RNA-pulsed DC cancer vaccine |
| CE/BZA | Conjugated estrogens/bazedoxifene |
| CEG | cisplatin-E therapeutic implant |
| CEM | CEM regimen |
| CEP-701 | Lestaurtinib |
| cetuximab-Zr-89 | Zirconium Zr 89-cetuximab |
| CEV | CEV regimen |
| CF/5-FU/L-OHP | FOLFOX regimen |
| CFB | Clofibrate |
| CFS | Chronic fatigue syndrome |
| CFZ | Carfilzomib |
| CgA | Chromogranin A |
| CGT | Calcium saccharate |
| Ch.14.18-IL2 | Immunocytokine NHS-IL2-LT |
| CHF | Chronic heart failure |
| CHIP | Clonal hematopoiesis of indeterminate potential; Iproplatin |
| chk1 inhibitor LY2606368 | Prexasertib |
| CHKA inhibitor TCD-717 | Choline kinase alpha inhibitor TCD-717 |
| CHOP | CHOP regimen |
| CHOPE | CHOPE regimen |
| CHPP | Continuous hyperthermic peritoneal perfusion; Hyperthermic intraperitoneal chemotherapy |
| CI-1033 | Canertinib dihydrochloride |
| CI-958 | Sedoxantrone trihydrochloride |
| CI-980 | Mivobulin isethionate |
| CI-994 | N-acetyldinaline |
| C-Ibza-MU | Namodenoson |
| CIFN | Interferon alfacon-1 |
| CIK | Cytokine-induced killer cells |
| CimaVax | Recombinant human EGF-rP64K/Montanide ISA 51 vaccine |
| CIN | Cervical intraepithelial neoplasia |
| CIS | Cancer Information Service |
| CISNET | Cancer Intervention and Surveillance Modeling Network |
| cis-UCA | Cis-urocanic acid |
| CKD | Chronic kidney disease |
| CKI | Compound Kushen injection |
| CLA | Conjugated linoleic acid |
| CLARITH | Clarithromycin |
| CLB | Chlorambucil |
| CLD | Chronic lung disease |
| CLIA | Clinical Laboratory Improvement Amendments |
| CLL | Chronic lymphocytic leukemia |
| CLL/SLL | Chronic lymphocytic leukemia/small lymphocytic lymphoma |
| CLOT | Clotrimazole |
| CLZ | Chlorozotocin |
| CMF | CMF regimen |
| CML | Chronic granulocytic leukemia; Chronic myelogenous leukemia; Chronic myeloid leukemia |
| CMM | Carubicin |
| CMML | Chronic myelomonocytic leukemia |
| CMS | Cerebellar mutism syndrome |
| CMV | Cytomegalovirus |
| CMV IE-1-specific CTL | Cytomegalovirus IE-1-specific cytotoxic T lymphocytes |
| CMV-PEP | CMV pp65 peptide |
| CNL | Ceramide nanoliposome |
| CNP | Carbon nanoparticle-based formulation |
| CNS | Central nervous system |
| CNV | Copy number variant |
| COG | Children's Oncology Group |
| COL18A1 | Endostatin |
| COPD | Chronic obstructive pulmonary disease |
| COPDAC | COPDAC regimen |
| COPP | COPP regimen |
| COPP-ABV | COPP-ABV regimen |
| Co-Q10 | Coenzyme Q10 |
| CoQ10 | Coenzyme Q10; Ubiquinone; Vitamin Q10 |
| COR | Cordycepin |
| COVID-19 | Coronavirus disease 19 |
| COX-2 | cyclooxygenase-2; Prostaglandin-endoperoxide synthase 2 |
| CP | Chlorambucil-prednisone regimen; CP regimen |
| CP regimen | Chlorambucil-prednisone regimen |
| CP-358,774 | Erlotinib hydrochloride; Tarceva |
| CP-4055 | Elacytarabine |
| CPAR | Attenuated corynebacterium parvum |
| CP/CPPS | Chronic prostatitis/chronic pelvic pain syndrome |
| CPE-C | Cyclopentenyl cytosine |
| CPFX | Ciprofloxacin |
| CpG 7909 | PF-3512676 |
| CpG ODN | CpG-28 oligodeoxynucleotide |
| CpG ODN GNKG168 | CpG oligodeoxynucleotide GNKG168 |
| CPG2 | Glucarpidase |
| CPHPC | Miridesap |
| CPM | Contralateral prophylactic mastectomy |
| CPR | Cardiopulmonary resuscitation |
| CPT | Captopril |
| CPV | Copovithane |
| CQS | Chloroquinoxaline sulfonamide |
| CRAd 5/3-delta24 | Conditionally replicative adenovirus 5/3-delta24 |
| CRC | Conditionally reprogrammed cell |
| cRGD-ZW800-1 | Fluorescent imaging agent cRGD-ZW800-1 |
| CRO | Contract Research Organization |
| CRP | C-reactive protein |
| CRPC | Castrate-resistant prostate cancer |
| CsA | Cyclosporine |
| CSF | Cerebrospinal fluid |
| CSP | Cystosarcoma phyllodes of the breast; Phyllodes tumor |
| CSPC | Androgen-dependent prostate cancer; Androgen-sensitive prostate cancer; Castrate-sensitive prostate cancer; Hormone-sensitive prostate cancer |
| CSS | Cause-specific survival |
| CT-2103 | Paclitaxel poliglumex; Paclitaxel polyglutamate; Xyotax |
| CT-2106 | Polyglutamate camptothecin |
| CT-322 | Angiocept; VEGFR-2 inhibitor CT-322 |
| CT53518 | Tandutinib |
| CTA | Computed tomography angiography; CT angiography |
| CTC | Circulating tumor cell |
| ctDNA | Circulating tumor DNA |
| CTL 19 | Allogeneic third-party suicide gene-transduced anti-HLA-DPB1*0401 CD4+ T cells CTL 19 |
| CTO | Carboxyamidotriazole orotate |
| Ctrx | Crotoxin |
| CTX | Cyclophosphamide |
| CTX/DOX/5-FU | CAF regimen |
| CTX/DOX/MOAB IDEC-C2B8/PRED/VCR | R-CHOP regimen |
| CTX/PCB/PRED/VCR | COPP regimen |
| Cu | Copper; Curcumin |
| Cu-64-TP3805 | Copper Cu 64 TP3805 |
| CUP | Cancer of unknown primary origin; Carcinoma of unknown primary |
| CVA | Cerebrovascular accident; Stroke |
| CVA21 | Gebasaxturev |
| CVP | CVP regimen |
| CyPat | Cyproterone acetate |
| CZP | Certolizumab pegol |